Implantable biofabricated neural pathway to restore brain circuitry

Innervace is a pioneering regenerative therapy company focused on developing innovative technologies to address neurological disorders, particularly Parkinson's disease. Their primary approach involves creating anatomically-inspired, implantable tissue pathways designed to replace lost neural connections resulting from brain degeneration or injury. This technology aims to reconstruct the nigrostriatal pathway, which is crucial for dopamine signaling and is often compromised in Parkinson's patients. Unlike traditional therapies that primarily manage symptoms, Innervace's strategy seeks to modify the disease by restoring the underlying neuroanatomy, potentially offering a more effective long-term solution.

The company has recently secured significant funding to advance its regenerative medicine platform, which includes a unique cell therapy modality. This funding will support the development of their lead program, which integrates bioengineered pathways with specific dopaminergic cell phenotypes sourced from collaborative research efforts. By focusing on reconstructing the primary neural pathways rather than merely increasing dopamine levels, Innervace aims to provide a differentiated therapeutic approach that could enhance treatment efficacy for patients suffering from Parkinson's disease and other neurological disorders.

United States

Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury.

Our lead program mimics the lost migrostriatal pathway in patients with Parkinson's disease (PD).

Innervace

Company Details